Cryptolepine 是一种口服有效的多活性生物碱,具有抗癌、抗菌、抗病毒、抗疟疾、抗炎、抗高血糖及缓解疼痛等多种特性,可作为 c-Myc、mTOR、NF-κB、HIF-1、MAPK 抑制剂及 AMPKα1/2 激活剂,能嵌入 DNA、抑制拓扑异构酶 II (Top II)、破坏线粒体动力学并诱导细胞凋亡 (apoptosis),同时具有抗疟原虫及胆碱酯酶抑制活性,可用于肿瘤 (黑色素瘤、肝细胞癌、乳腺腺癌等)、疟疾、炎症性疾病及糖尿病的相关研究,特别是抑制肿瘤生长与抗疟原虫感染。
产品编号: MS-O08090 CAS No.: 480-26-2 分子式: C16H12N2 分子量: 232.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Cryptolepine 是一种口服有效的多活性生物碱,具有抗癌、抗菌、抗病毒、抗疟疾、抗炎、抗高血糖及缓解疼痛等多种特性,可作为 c-Myc、mTOR、NF-κB、HIF-1、MAPK 抑制剂及 AMPKα1/2 激活剂,能嵌入 DNA、抑制拓扑异构酶 II (Top II)、破坏线粒体动力学并诱导细胞凋亡 (apoptosis),同时具有抗疟原虫及胆碱酯酶抑制活性,可用于肿瘤 (黑色素瘤、肝细胞癌、乳腺腺癌等)、疟疾、炎症性疾病及糖尿病的相关研究,特别是抑制肿瘤生长与抗疟原虫感染。

生物实验数据

生物活性 Cryptolepine is an orally active multi-activity alkaloid possessing anticancer, antibacterial, antiviral, antimalarial, anti-inflammatory, antihyperglycemic, and analgesic properties; it acts as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, and MAPK and an activator of AMPKα1/2, intercalates into DNA, inhibits topoisomerase II (Top II), disrupts mitochondrial dynamics, and induces apoptosis, while also exhibiting antiplasmodial and cholinesterase inhibitory activities; it is applicable to research on tumors (melanoma, hepatocellular carcinoma, mammary adenocarcinoma, etc.), malaria, inflammatory diseases, and diabetes, particularly for inhibiting tumor growth and countering Plasmodium infection.
IC50 & Target

p38 MAPK

 

Topoisomerase II

 

hAChE

485 nM (IC50)

BChE

699 nM (IC50)

eel AChE

267 nM (IC50)

HIF-1α

 

体外研究
(In Vitro)

Cryptolepine (2.5-7.5 μM;24 h) 以浓度依赖的方式诱导 A375 和 Hs294t 黑色素瘤细胞发生线粒体耗竭,并激活 AMPKα1/2-LKB1通路。
Cryptolepine (2.5-10 μM) 可抑制 LPS 诱导的 RAW 264.7 细胞中一氧化氮的生成,并通过抑制 NF-κB 激活过程中的 DNA 结合活性来发挥抗炎作用。
Cryptolepine (0.5-2 μM;24 h) 以剂量依赖的方式抑制经 200 ng/mL IL-6 处理 24 h 的人肝癌 HepG2 细胞中 p-STAT3 和 IL-23 的水平。
Cryptolepine (1-20 μM;缺氧条件;24 h) 以时间和剂量依赖的方式降低 T47D、4T1、MCF-7 和 MDA-MB-231 乳腺癌细胞中缺氧诱导的 HIF-1α 蛋白水平。
Cryptolepine (0-100 μg/mL;72 h),对 Jurkat 白血病细胞系具有细胞毒性,其 CC50值<62.56 μg/mL。
Cryptolepine (10 μM-1.69×10-4 μM;48 h) 抑制恶性疟原虫 (NF54) IV/V 期晚期配子体的活力,IC50为 1965 nM。
Cryptolepine (0.5-1.2 μM;48 h) 可在 IC30 (0.5 μM) 和 IC50 浓度下强效抑制未受刺激及受 WNT3a 刺激的 DLD1 结直肠癌细胞的迁移。

Western Blot Analysis

Cell Line: A375, Hs294t
Concentration: 2.5, 5.0, 7.5 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent decrease in protein levels of Mfn1, Mfn2, Opa1, and Drp1 compared to vehicle-treated controls.
Reduced total and phosphorylated mTOR protein levels, as well as phosphorylation of p70S6K and 4E-BP1 (downstream targets) in a concentration-dependent manner; total p70S6K and 4E-BP1 levels were unaffected.
Reduced levels of PGC-1α, SIRT1, Opa1, and c-Myc proteins in a concentration-dependent manner.

ELISA Assay

Cell Line: human hepatoma HepG2 cells treated with IL-6
Concentration: 0.5,1,2 μM (in the presence of 200 ng/mL IL-6)
Incubation Time: 24 h
Result: Suppressed p-STAT3 and IL-23 levels in a dose-dependent fashion.
Additively suppressed p-STAT3 and IL-23 levels when co-treated with 5 μM niclosamide at 0.5 μM.

Western Blot Analysis

Cell Line: T47D, 4T1, MCF-7, and MDA-MB-231 breast cancer cells
Concentration: 1-20 μM
Incubation Time: 24 h under hypoxia
Result: Reduced hypoxia-induced HIF-1α protein levels in T47D, 4T1, MCF-7, and MDA-MB-231 breast cancer cells.
Dose-dependently suppressed hypoxia-induced protein expression of GLUT-1, LDHA, PFKFB3, p-PFKFB3, and PFK-1.
Dose-dependently decreased the phosphorylation of Ras, p-c-Raf, p-MEK1/2, p-ERK1/2 (MAPK pathway), p-mTOR, p-p70S6K, p-4E-BP1, and p-eIF4E (mTOR pathway and eIF4E phosphorylation); increased p-AMPKα and p-TSC2.
体内研究
(In Vivo)

Cryptolepine (10 mg/kg;i.p.;每周 3 次;持续 24 天) 通过破坏线粒体动力学与生物发生,抑制无胸腺裸鼠的黑色素瘤肿瘤生长。
Cryptolepine (7.0-112.6 mg/kg/d;s.c.;每日,4 天) 未显著降低小鼠体内 P. berghei 的原虫血症水平。
Cryptolepine (10-40 mg/kg;i.p. or p.o.;每日;4 天) 在大鼠急性炎症模型中表现出剂量依赖性抗炎活性,且不会诱发胃损伤。
Cryptolepine (10-40 mg/kg;i.p.) 在角叉菜胶诱导的大鼠足肿胀模型中呈现剂量依赖性抗炎活性,如抑制 LPS 诱导的微血管通透性;Cryptolepine (10-40 mg/kg; i.p.) 还在乙酸诱导的小鼠扭体模型中表现出剂量依赖性镇痛活性。
Cryptolepine (5-20 mg/kg;i.p.;每 2 天 1 次;共 7 次) 可剂量依赖性地抑制 BALB/c 小鼠体内 4T1 肿瘤的生长,其中 20 mg/kg 剂量组的肿瘤生长抑制率 (TGI) 达 71.5%,其作用机制为抑制HIF-1介导的糖酵解与 ATP 生成。

Animal Model: athymic nude mice (female, 4–5 weeks of age)
Dosage: 10 mg/kg
Administration: i.p.; 3 days/week; 24 days
Result: Reduced tumor volume by 68%; reduced average wet tumor weight by 61%; reduced tumor ATP content by 32%; reduced levels of phosphorylated Drp1, c-Myc, SIRT1, and PGC-1α proteins; enhanced phosphorylation of AMPKα1/2; reduced phosphorylation of 4E-BP1.
Animal Model: Swiss albino (TO strain, male, mean weight 25 g, Eperythrozoon-free, Plasmodium berghei-infected)
Dosage: 7.0, 14.1, 28.2, 56.3, 112.6 mg/kg/d
Administration: s.c.; daily; 4 days
Result: Showed no significant effect on P. berghei parasitaemia, with mean parasitaemia values ranging from 33.04% to 46.44% and no significant reduction compared to control mice.
Animal Model: carrageenan-induced paw oedema model, LPS-induced microvascular permeability model, and acetic acid-induced writhing model in Wistar rats (male, 120–200 g)
Dosage: 10, 20, 40 mg/kg
Administration: i.p.; single dose 1 hour before carrageenan injection
Result: 1. Produced statistically significant inhibition of paw oedema formation in a dose-dependent manner at the third hour (oedema peak).
2. Significantly inhibited LPS-induced microvascular permeability in a dose-dependent manner.
3. Inhibited carrageenan-induced pleurisy by 23.6%, 35.3%, and 51.2% at 10, 20, and 40 mg/kg, respectively, in a dose-dependent manner.
4. Significantly inhibited writhing in a dose-dependent manner.
Animal Model: BALB/c (female, 4–6 weeks old, 18–22 g, 4T1 tumor xenograft model)
Dosage: 5, 10, 20 mg/kg
Administration: i.p.; once every 2 days; seven injections
Result: Reduced tumor weight with tumor growth inhibition (TGI) values of 45.8% (10 mg/kg) and 71.5% (20 mg/kg).
Dose-dependently decreased HIF-1α protein expression in tumors; reduced tumor lactic acid levels by 54.1% (10 mg/kg) and 68.4% (20 mg/kg).
Dose-dependently reduced tumor ATP production.
Decreased the ratio of phosphorylated eIF4E to total eIF4E in tumors at 10 and 20 mg/kg doses.

化学信息

分子量 232.29
分子式 C16H12N2
CAS No. 480-26-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础